Cystic fibrosis patients in England will have access to life-extending drugs after the state-funded health service said it had agreed a pricing deal with manufacturer Vertex Pharmaceuticals. England’s National Health Service (NHS) has been negotiating with Vertex for years about supplying Orkambi, a combination drug that improves lung function. The U.S. company had wanted to charge around 100,000 pounds ($129,000) a year for a course of Orkambi, according to reports. …read more
Source:: Yahoo Finance
